July 26, 2026
An FDA Panel Voted Yes on BPC-157. Here Is What That Actually Means.
On July 23 to 24, 2026, an FDA advisory committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for pharmacy compounding, and voted against Emideltide (DSIP). The vote is not FDA approval — here is what changed and what did not.
If your feed lit up this week with "BPC-157 just got FDA approved," take a breath — that is not what happened. On July 23 and 24, 2026, an FDA advisory committee voted on whether seven peptides should be added to the list of substances licensed compounding pharmacies are allowed to produce. That is a real, meaningful step. It is not drug approval.
What actually happened
The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides over two days and voted on each:
| Peptide | Nominated use | Vote | Outcome |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | 8 to 6, 1 abstention | Recommended |
| KPV | Wound healing / inflammation | 8 to 6, 1 abstention | Recommended |
| TB-500 | Tissue repair | In favor | Recommended |
| MOTS-c | Metabolic support | In favor | Recommended |
| Epitalon | Insomnia | 7 to 5, 1 abstention | Recommended |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | 8 to 5 | Recommended |
| Emideltide (DSIP) | Insomnia, narcolepsy, opioid withdrawal | 6 to 7, 1 abstention | Rejected |
Six of the seven were recommended. Emideltide, marketed under the name DSIP in most research-peptide communities, was voted down.
What a "yes" vote does and does not mean
The committee was voting on whether these substances should be added to the 503A Bulks List — the list that governs what a state-licensed compounding pharmacy is legally allowed to prepare from raw ingredients under a physician's prescription. A "yes" vote here means the committee thinks compounding pharmacies, not the unregulated gray market, should be allowed to make the substance.
It does not mean:
- The FDA has approved BPC-157, or any of the other five, as a safe and effective drug.
- Large-scale human clinical trials now exist.
- The substance is legal to sell over the counter or ship as a finished product.
The vote is also non-binding. FDA staff can, and sometimes do, go a different direction from an advisory committee. The agency now has to run a formal rulemaking process, which typically takes months to years and includes a public comment period, before anything changes for real.
Why FDA's own scientists said no
This is the part getting lost in the celebratory posts: the committee overrode its own agency's scientific staff. FDA reviewers raised, among BPC-157 and its peers, concerns including a lack of controlled human trial data, incomplete chemical characterization, potential impurities from the manufacturing process, and (for Epitalon specifically) a signal for carcinogenicity in nonclinical data. One committee member who voted no on BPC-157 noted that the existing randomized data suggested it performed no better than placebo, and that a risk like liver injury would not reliably be caught through patient self-reporting alone.
The majority who voted yes leaned heavily on a different argument: that patients are already buying these compounds from unregulated online sellers, and that routing access through a licensed pharmacy and a physician's prescription is safer than the status quo, even without full trial data. Both sides have a point, and neither changes the underlying evidence.
What changes for you today: nothing
If you already track BPC-157, TB-500, or any of the other six peptides, this vote does not change their evidence base, their legal status, or how they show up in your compound library. They remain unapproved by the FDA, and the science behind them is still mostly preclinical (animal studies) or limited to small, uncontrolled human pilot work. If and when the FDA completes rulemaking, we will update our library notes to reflect it.
What to log if you are tracking any of these
Regardless of where the regulatory process lands, careful logging is what turns an anecdote into something you can actually evaluate:
- Dose and date, every administration.
- Source or batch, especially while these remain outside pharmacy-grade regulation.
- Injection site, rotated and recorded.
- Side effects, timed relative to the dose, however minor they seem.
- A defined outcome you are actually trying to move, so you are reading data instead of vibes six weeks from now.
TrackPep lets you log each compound separately with its own dose history and side-effect timeline, so if the regulatory picture changes, your data already tells the real story.
Educational only — not medical advice. None of the peptides discussed here are FDA-approved drugs. The advisory committee vote is non-binding and does not change their current legal or clinical status. Always consult a licensed healthcare provider before starting, stopping, or changing any protocol.